Emergence of High-Avidity Melan-A–Specific Q2 Clonotypes as a Reflection of Anti–PD-1 Q3 Clinical Efficacy

Abstract : Therapeutic strategies using anti-PD-1-blocking antibodies reported unparalleled effectiveness for melanoma immunotherapy, but deciphering immune responses modulated by anti-PD-1 treatment remains a crucial issue. Here, we analyzed the composition and functions of the large Melan-A-specific T-cell repertoire in the peripheral blood of 9 melanoma patients before and after 2 months of treatment with anti-PD-1. We observed amplification of Melan-A-specific Vß subfamilies undetectable before therapy (thereafter called emerging Vß subfamilies) in responding patients, with a predominant expansion in patients with a complete response. These emerging Vß subfamilies displayed a higher functional avidity for their cognate antigen than Vß subfamilies not amplified upon anti-PD-1 therapy and could be identified by a sustained coexpression of PD-1 and TIGIT receptors. Thus, in addition to the emergence of neoantigen-specific T cells previously documented upon anti-PD-1 therapy, our work describes the emergence of high-avidity Melan-A-specific clonotypes as a surrogate marker of treatment efficacy.
Type de document :
Article dans une revue
Cancer Research, American Association for Cancer Research, 2017, 77 (24), pp.7083 - 7093. 〈10.1158/0008-5472.CAN-17-1856〉
Liste complète des métadonnées

Littérature citée [47 références]  Voir  Masquer  Télécharger

http://www.hal.inserm.fr/inserm-01636933
Contributeur : Elizabeth Bernardo <>
Soumis le : jeudi 25 janvier 2018 - 11:52:36
Dernière modification le : jeudi 5 avril 2018 - 10:37:03

Fichier

 Accès restreint
Fichier visible le : jamais

Connectez-vous pour demander l'accès au fichier

Identifiants

Collections

Citation

Sylvain Simon, Virginie Vignard, Emilie Varey, Tiphaine Parrot, Anne-Chantal Knol, et al.. Emergence of High-Avidity Melan-A–Specific Q2 Clonotypes as a Reflection of Anti–PD-1 Q3 Clinical Efficacy. Cancer Research, American Association for Cancer Research, 2017, 77 (24), pp.7083 - 7093. 〈10.1158/0008-5472.CAN-17-1856〉. 〈inserm-01636933v2〉

Partager

Métriques

Consultations de la notice

84